go-v.orgdoi

Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study

Eva Lesén, Daniel Granfeldt, Anthony Berthon, Jérôme Dinet, Aude Houchard, Peter Myrenfors, Åse Björstad, Ingela Björholt, Anna‐Karin Elf, Viktor Johanson · Journal of Cancer · 2019

  • DOI 10.7150/jca.32381
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2019

Abstract

Background: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are neoplasms derived from the endocrine system in the gastrointestinal tract and pancreas.Treatment options include surgery; pharmacological treatments like somatostatin analogues (SSA), interferon alpha, molecular targeted therapy and chemotherapy; and peptide receptor radionuclide therapy.The objective of this study was to describe treatment patterns and survival among patients with metastatic GEP-NET grade 1 or 2 in Sweden.Methods: Data was obtained via linkage of nationwide registers.Patients diagnosed with metastatic GEP-NET grade 1 or 2 in Sweden between 2005 and 2013 were included (n=811; National population).In addition, medical chart review was performed for the subpopulation diagnosed at Sahlgrenska University Hospital, Gothenburg (n=127; Regional population).Treatment patterns, including treatment sequences, and overall survival were assessed.Results: Most patients had small intestinal NET (76%).In the regional population, 72% had grade 1 tumours; 50% had functioning tumours.The two most common first-line treatments were surgery (57%) and SSA (25%).After first-line surgery, 46% received SSA, while 40% had no further treatment.After first-line SSA, 52% received surgery, while 27% had no further treatment.Overall median survival time from date of diagnosis was 7.0 years (95% CI 6.2-not reached).Among patients with distant metastases, pancreatic NET (vs.small intestinal NET) was associated with poorer survival (HR 1.9; 95% CI 1.1-3.3),as were liver metastases (HR 3.2; 95% CI 1.5-7.0).Conclusions: First-line surgery was typically followed by SSA or no further treatment.Among patients with distant metastases, pancreatic NET or liver metastases were associated with a poorer survival.

Open the resolved locator · 10.7150/jca.32381

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:21 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v10p6876.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.